PDF(Pubmed)
Abstract：
UNASSIGNED: Basal cell carcinoma (BCC) is treated with local surgery or noninvasive treatment modalities. If a BCC remains untreated, it can develop into a locally advanced BCC or a metastatic BCC.
UNASSIGNED: Here we report in detail the management of three complex advanced BCC (aBCC) after treatment failure with vismodegib. On all tumors, next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed; subsequently, patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anticancer drugs based on the molecular tumor profile. All patients showed partial response or stable disease following treatment with second line PD-1 inhibitors with an average duration of response of 12.3 months.
UNASSIGNED: Immunotherapy can be a treatment option for aBCC resistant to hedgehog pathway inhibitor treatment. However, despite the high tumor mutational burden of aBCCs, immunotherapy does not always lead to a long response. Rechallenge or combining treatment of hedgehog inhibitors and PD-1 inhibitors by parallel or alternating cycles may be a strategy to lengthen the treatment response.
UNASSIGNED: Here we report in detail the management of three complex advanced BCC (aBCC) after treatment failure with vismodegib. On all tumors, next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed; subsequently, patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anticancer drugs based on the molecular tumor profile. All patients showed partial response or stable disease following treatment with second line PD-1 inhibitors with an average duration of response of 12.3 months.
UNASSIGNED: Immunotherapy can be a treatment option for aBCC resistant to hedgehog pathway inhibitor treatment. However, despite the high tumor mutational burden of aBCCs, immunotherapy does not always lead to a long response. Rechallenge or combining treatment of hedgehog inhibitors and PD-1 inhibitors by parallel or alternating cycles may be a strategy to lengthen the treatment response.
摘要：
■基底细胞癌（BCC）采用局部手术或非侵入性治疗方式进行治疗。如果BCC未得到治疗，它可以发展成局部晚期BCC或转移性BCC。
■在这里，我们详细报告了使用vismodegib治疗失败后三种复杂的高级BCC（aBCC）的管理。在所有肿瘤上，在个性化癌症治疗中心-02（CPCT-02）研究中进行了下一代DNA测序；随后，患者被纳入药物重新发现方案（DRUP）试验，其中基于分子肿瘤谱，使用市售靶向抗癌药物开始治疗。所有患者在用二线PD-1抑制剂治疗后表现出部分反应或疾病稳定，平均反应持续时间为12.3个月。
■免疫治疗可以成为抗hedgehog途径抑制剂治疗的aBCC的治疗选择。然而,尽管aBCC的肿瘤突变负担很高，免疫疗法并不总是导致长时间的反应。通过平行或交替循环再激发或组合治疗hedgehog抑制剂和PD-1抑制剂可能是延长治疗反应的策略。
■在这里，我们详细报告了使用vismodegib治疗失败后三种复杂的高级BCC（aBCC）的管理。在所有肿瘤上，在个性化癌症治疗中心-02（CPCT-02）研究中进行了下一代DNA测序；随后，患者被纳入药物重新发现方案（DRUP）试验，其中基于分子肿瘤谱，使用市售靶向抗癌药物开始治疗。所有患者在用二线PD-1抑制剂治疗后表现出部分反应或疾病稳定，平均反应持续时间为12.3个月。
■免疫治疗可以成为抗hedgehog途径抑制剂治疗的aBCC的治疗选择。然而,尽管aBCC的肿瘤突变负担很高，免疫疗法并不总是导致长时间的反应。通过平行或交替循环再激发或组合治疗hedgehog抑制剂和PD-1抑制剂可能是延长治疗反应的策略。
